Brief: Biofrontera Announces New Patent Protection On Ameluz Until 2043
15/05/2025 19:51
May 15 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA INC. ANNOUNCES NEW PATENT PROTECTION ON AMELUZ® UNTIL 2043 AND THE COMPLETION OF PATIENT ENROLLMENT IN PHASE 2B STUDY OF AMELUZ® (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS BIOFRONTERA INC - EXPECTS LAST-PATIENT-OUT IN Q3 2025 FOR AMELUZ TRIAL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales